Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489812 | 0.78 | CYP3A4 (0.46) | HTTSMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL13191461 | 0.78 | HDAC1 (0.41) | ALDH1A1HTTSMN1; SMN2TSHRMEN1 | |
| SCHEMBL14135197 | 0.78 | MCL1 (0.38) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| SCHEMBL12386648 | 0.78 | ALDH1A1 (0.43) | ALDH1A1PRSS1PRSS2PRSS3POLB | |
| SCHEMBL8272774 | 0.76 | ALDH1A1 (0.42) | ALDH1A1PRSS1PRSS2PRSS3POLB | |
| SCHEMBL10269393 | 0.72 | ESR2 (0.58) | ALDH1A1 | |
| SCHEMBL14436669 | 0.69 | CYP1A2 (0.32) | ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL13191460 | 0.69 | — | — | |
| SCHEMBL20830925 | 0.69 | ALDH1A1 (0.36) | ALDH1A1PRSS1PRSS2PRSS3POLB | |
| SCHEMBL11950344 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017053426-A1 | ISOMERIC AND ASYMMETRIC MOLECULAR GLASS MIXTURES FOR OLED AND OTHER ORGANIC ELECTRONICS AND PHOTONICS APPLICATIONS | MOLECULAR GLASSES, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-8431243-B2 | Substituted 2-Phenyl quinoline complex with Iridium; high device efficiency, stability, and processibility | UNIVERSAL DISPLAY CORPORATION (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006474-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20080261076-A1 | Substituted 2-Phenyl quinoline complex with Iridium; high device efficiency, stability, and processibility | UNIVERSAL DISPLAY CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261076-A1 | Substituted 2-Phenyl quinoline complex with Iridium; high device efficiency, stability, and processibility | PCID2, ICMT, ORAI2 | ALDH1A1 3830/4885PRSS1 3161/4885PRSS2 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.